> Intellectual property
Theranexus' technology is protected by a portfolio of four families of patents covering combinations (compositions of matter) and their specific applications (methods of treatment) in the development of treatments for psychiatric and neurological disorders. Theranexus endeavors to safeguard its market position and intellectual property by establishing additional, comprehensive patent groups. Theranexus' strategy involves continuously strengthening this portfolio by adding new patents in order to consolidate its leadership position in innovative combinations targeting neuroglial interaction.
| Family of patents 1 (platform patent) |
Family of patents 2 | Family of patents 3 | Family of patents 4 | |
| Products | Anti-connexin agent + psychotropic molecule | THN201 Dementia |
THN102 Narcolepsy / Parkinson's |
THN101 Neuropathic pain |
| Expiry date | 2029 | 2032 | 2034 | 2036 |
| Geographic regions targeted |
The four families of patents covering Theranexus' combinations are presented below.
Family 1
WO2010029131 - "Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs" - jointly owned by the CEA/Bio-Modeling Systems (BMSystems), for which Theranexus has a worldwide exclusive license.
Family 2
WO2013064579 - "Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors" - owned by the CEA, for which Theranexus has a worldwide exclusive license.
Family 3
WO2015011246 - "Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug" - owned by the CEA, for which Theranexus has a worldwide exclusive license.
Family 4
WO2017009472 - "Use of amitriptyline for blocking brain hemichannels and method for potentiating its effect in vivo" - owned by Theranexus.